跳至主要内容
临床试验/NCT02204267
NCT02204267已完成不适用

Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke

Charite University, Berlin, Germany2 个研究点 分布在 1 个国家目标入组 3,470 人开始时间: 2014年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
3,470
试验地点
2
主要终点
Number of patients on oral anticoagulation (NOAC or VKA)

研究概览

简要总结

Investigator-initiated prospective randomized multicentre study to uncover the true burden of paroxysmal atrial fibrillation in a representative population of acute stroke patients without known atrial fibrillation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acute ischemic stroke or transitory ischemic attack (with clinical deficit on enrolment or MRI detected acute brain lesion on admission)
  • Age ≥ 18 years
  • Written or oral informed consent
  • Stroke unit admission within 72 hours after stroke onset
  • Start of standardized prolonged ECG monitoring within 24 hours after admission to the stroke unit
  • Willingness to take part in the planned follow up examinations

排除标准

  • Known atrial fibrillation
  • Atrial fibrillation detected by ECG on admission
  • Atrial fibrillation detected prior study enrollment on the stroke unit
  • Life expectancy < 1 year (before actual stroke)
  • Life expectancy < 1 month (after actual stroke)
  • Indication for oral anticoagulation other than atrial fibrillation (e.g. mechanical heart valve)
  • Severity level according National Institute of Health Stroke Scale (NIHSS) score > 22
  • Participation in an interventional trial

结局指标

主要结局

Number of patients on oral anticoagulation (NOAC or VKA)

时间窗: 12 months

Number of study patients on oral anticoagulation (NOAC or VKA) at 12 months after the index stroke either randomized to standardized prolonged ECG monitoring in-hospital or those randomized to usual stroke unit diagnostic procedures alone.

次要结局

  • Number of stroke patients with newly detected atrial fibrillation(7 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Matthias Endres

Prof. Dr. med.

Charite University, Berlin, Germany

研究点 (2)

Loading locations...

相似试验